CTY
City Therapeutics Inc.
There isn't enough reported data to score CTY yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CTY Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Healthy | |
| Healthy | |
| Healthy |
CTY's profitability, cash flow and balance sheet are currently healthy, but its revenue is weak.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CTY PE Valuation
CTY has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CTY Forward outlook
There aren't enough analyst estimates for CTY to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CTY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2020 | $0.00 | $0.00 |
| Q1 2020 | $0.00 | $0.00 |
| Q4 2019 | $0.00 | $0.00 |
| Q3 2019 | $0.00 | $0.00 |
| Q2 2019 | $0.00 | $0.00 |
| Q1 2019 | $0.00 | $0.00 |
| Q4 2018 | $0.00 | $0.00 |
| Q3 2018 | $0.00 | $0.00 |
CTY lost $0.00 per share over the past year, a bigger loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
CTY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2020 | $524M | -74% |
| Q1 2020 | $1.9B | -6.7% |
| Q4 2019 | $2B | -4.8% |
| Q3 2019 | $2B | -5.1% |
| Q2 2019 | $2.1B | -2.4% |
| Q1 2019 | $2.1B | -3.5% |
| Q4 2018 | $2.1B | 0% |
| Q3 2018 | $2.1B | +0.4% |
UNH has the stronger quarterly revenue trend. Revenue is down 74% for CTY versus down 0.4% for UNH.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2020 | 130% | +93 points |
| Q1 2020 | 41% | +3.6 points |
| Q4 2019 | 31% | -1.3 points |
| Q3 2019 | 37% | +3.3 points |
| Q2 2019 | 37% | +6.8 points |
| Q1 2019 | 37% | +7.3 points |
| Q4 2018 | 32% | +4 points |
| Q3 2018 | 33% | +7.2 points |
CTY's operating margin was 130% last quarter, up 93 points from the same quarter a year ago, near the top of its range since 2013.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
CTY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2020 | $410M | -25% |
| Q1 2020 | $468M | +5.4% |
| Q4 2019 | $737M | -11% |
| Q3 2019 | $552M | -19% |
| Q2 2019 | $544M | -34% |
| Q1 2019 | $444M | +6.5% |
| Q4 2018 | $831M | +120% |
| Q3 2018 | $679M | +231% |
CTY has the stronger cash trend. Its trailing FCF is up 27% versus its history, compared with UNH at up 5.2%.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
CTY Total Shares
| Quarter | Spent |
|---|---|
| Q2 2020 | $3M |
| Q1 2020 | $8M |
| Q4 2019 | $1M |
| Q3 2019 | $4M |
| Q2 2019 | $2M |
| Q1 2019 | $9M |
| Q4 2018 | $1M |
| Q3 2018 | $5M |
CTY spent $16M buying back its own shares over the past year, down 5.9% from the year before.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has 902M diluted shares, down 0.7% from a year ago, with $5B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
CTY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | 1.3x | Healthy |
| Q1 2020 | 1.3x | Healthy |
| Q4 2019 | 1.6x | Healthy |
| Q3 2019 | 1.4x | Healthy |
| Q2 2019 | 1.4x | Healthy |
| Q1 2019 | 1.4x | Healthy |
| Q4 2018 | 1.5x | Healthy |
| Q3 2018 | 1.5x | Healthy |
CTY's net debt is about 1.3 years of its operating earnings (EBITDA), about the same as a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CTY Weekly Momentum
As of the close on Nov 12, 2026: $18.98.
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CTY PE vs Healthcare Sector
CTY has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CTY Weekly Moving Averages
As of the close on Nov 12, 2026: $18.98.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
CTY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $22.4 | $19.0 | -15% |
It's down 15% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CTY on returns for 2026, with the stronger performance.